Pfizer said it is working closely with its biotech partners to “ensure continuity and the successful transition of work.” (iStock/Getty Images Plus) As pharmas like Eli Lilly and Roche bolster their ...

Alongside a series A fundraise, OTR Therapeutics disclosed that it had acquired "a preclinical program with best-in-class potential for neurological diseases." (iStock / Getty Images Plus) Pfizer’s VC ...

Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space.

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Pfizer-backed biotech landed ...

The chaos at Danish Big Pharma Novo Nordisk is spilling across the Atlantic as the drugmaker launches a risky bid to snatch the anti-obesity biotech Metsera out of Pfizer’s grip. Novo has suffered ...